Helical Needle Transendocardial Delivery of Autologous Bone Marrow Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies fail to effectively address or reverse the detrimental effects of chronic myocardial infarction, where infracted tissue has transformed into scar tissue, leading to ventricular remodeling and heart failure.

Innovation Solution

Injecting autologous bone marrow-derived mononuclear cells, specifically CD-34, CD-133, and CD-90 positive cells, into the myocardium near or at the chronic infarcted tissue sites to promote tissue repair.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional therapies are used for chronic myocardial infarction, then the treatment is simple and readily available, but the therapy fails to effectively address or reverse the detrimental effects of chronic myocardial infarction

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidcomplexity of treatment procedure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses bone marrow-derived mononuclear cells as an intermediary substance to mediate between the damaged myocardial tissue and the healing process. These cells are injected into the infarcted myocardium to promote tissue repair and reverse remodeling, effectively addressing the limitations of conventional therapies while maintaining procedural simplicity through a single injection approach

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If no therapy is applied for chronic myocardial infarction, then the treatment procedure remains simple, but ventricular remodeling progresses leading to ventricular dilation and heart failure

Engineering Contradiction:

Improveprevention of ventricular remodelingVSAvoidease of treatment implementation

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent employs preliminary action by injecting bone marrow-derived mononuclear cells into the chronically infarcted myocardium to proactively prevent further ventricular remodeling and dilation. This single injection delivers reparative cells in advance to counteract the progressive remodeling process, effectively preventing heart failure while maintaining treatment simplicity

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If conventional therapies are used for acute myocardial infarction, then immediate post-infarct care is provided, but no significant therapy exists for amelioration or reversal of chronic myocardial infarction

Engineering Contradiction:

Improveapplicability to chronic infarctionVSAvoidtherapeutic efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies parameter changes by transitioning from treating acute myocardial infarction to treating chronic myocardial infarction, and from using conventional pharmacological therapies to using cellular therapy with bone marrow-derived mononuclear cells. This fundamental parameter change in treatment modality enables effective therapy for chronic infarction where previously no significant treatment existed

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9517199B2Treatment for chronic myocardial infarct

Publication Date: 2016.12.13 BIOCARDIA INC

AI summary

A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).